IGF1R and cancer: Furthermore, in a study by Lovly et al.; it is shown that combination therapy with Crizotinib, a selective tyrosine kinase inhibitor, and an IGF-1 receptor (IGF-1R)-inhibitor has therapeutic effect in lung cancer via sensitizing the cancer cells to Crizotinib by inhibiting the IGF signaling pathway activation [139].